BIOPHARMA
ByWith the Only FDA-Cleared Blood Test for Alzheimer’s Risk, Can Roche’s ADLM 2026 Portfolio Bring Earlier Answers to Patients 55 and Older?
Key Highlights A Landmark Showcase Addressing Healthcare’s Systemic Workforce Challenges Roche’s presence at ADLM 2026 reflects a clear…
Can a $10 Billion Pipeline Opportunity Help Novartis Outrun Its Entresto Patent Cliff After a $5.94 Billion Profit Beat?
Key Highlights A Landmark Quarter Reinforcing Confidence in Novartis’ Growth Trajectory Novartis’ second-quarter results send an encouraging signal…
Approved Two Months Early, Can GSK’s Jideytro Become the Blueprint for Faster Breakthrough Therapies in NSCLC?
Key Highlights A Landmark Approval Reflecting the Strength of GSK’s Oncology Push GSK’s announcement that the FDA has…
Can Insilico Medicine’s 9-Month AI Drug Discovery Record in China Rewrite the Global Timeline for Bringing New Medicines to Patients?
Key Highlights A Landmark Shift in How Fast New Medicines Can Reach Patients Insilico Medicine’s disclosure that it…
GSK Bets on Cambridge: Inside the R&D Push Behind a £40 Billion Sales Target
A look at GSK’s new Cambridge research centre, its cost-cutting programme, and what a 75% profit drop tells…
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma GLOBAL BIOPHARMA…
